白金系化学療法・腎毒性 - 市場考察、疫学、市場予測（2032年）

主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）の白金系化学療法・腎毒性の総市場規模は、2021年に6億5,480万米ドルであり、調査期間中（2019年～2032年）に上昇すると予測されています。

当レポートでは、白金系化学療法・腎毒性の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 白金系化学療法・腎毒性市場の概要

• 白金系化学療法・腎毒性の市場シェア分布：治療法別（2019年）
• 白金系化学療法・腎毒性の市場シェア分布：治療法別（2032年）

第4章 白金系化学療法・腎毒性のエグゼクティブサマリー

第5章 主な出来事

第6章 疫学と市場調査手法

第7章 疾患の背景と概要：白金系化学療法・腎毒性

• イントロダクション
• 白金系化学療法剤
• 白金製剤の毒性のメカニズム
• シスプラチン腎毒性
• 腎症状
• シスプラチン腎毒性の危険因子
• 病態生理学
• 診断
• 治療

第8章 ペイシェントジャーニー

第9章 疫学と患者数

• 主な調査結果
• 前提条件と根拠：主要7市場
• 主要7市場の疫学シナリオ
• 米国の疫学シナリオ
• 欧州4ヶ国・英国の疫学シナリオ
• 日本の疫学シナリオ

第10章 白金系化学療法・腎毒性の臨床試験における主な評価項目

第11章 新たな治療法

第12章 コンジョイント分析

• 属性分析
• 主な市場予測の前提条件

第13章 白金系化学療法・腎毒性：主要7市場の分析

• 主な調査結果
• 市場の見通し
• 主要7市場の白金系化学療法・腎毒性の市場規模
• 米国の白金系化学療法・腎毒性の市場規模
• 欧州4ヶ国・英国の白金系化学療法・腎毒性の市場規模
• 日本の白金系化学療法・腎毒性の市場規模

第14章 KOLの見解

第15章 SWOT分析

第16章 アンメットニーズ

第17章 付録

第18章 DelveInsightのサービス内容

第19章 免責事項

第20章 DelveInsightについて

List of Tables

• Table 1: Summary of Platinum-based Chemotherapy and Nephrotoxicity, Market, Epidemiology, and Key Events (2019-2032)
• Table 2: Summary of Hydration and Supplementation Recommendations to Prevent Nephrotoxicity From Cisplatin
• Table 3: Assessment of Renal Function Before and After Cancer Drug Therapy
• Table 4: Prevention of Decreased Renal Function During Cancer Drug Therapy
• Table 5: Recommendations
• Table 6: Total Incident cases of cancers using platinum based chemotherapy in the 7MM, in Thousands (2019-2032)
• Table 7: Stage-wise Incident Cases of Cancer in the 7MM, in Thousands (2019-2032)
• Table 8: Line-wise Chemo Treated Cases in the 7MM, in Thousands (2019-2032)
• Table 9: Platinum Therapy Treated Cases in the 7MM, in Thousands (2019-2032)
• Table 10: Platin based Chemotherapy use by cancers Cases in the 7MM, in Thousands (2019-2032)
• Table 11: Total Platinum Induced Nephrotoxicity (AKI) Cases in the 7MM, in Thousands (2019-2032)
• Table 12: Total Incident cases of cancers using platinum based chemotherapy in the US, in Thousands (2019-2032)
• Table 13: Stage-wise Incident Cases of Cancer in the US, in Thousands (2019-2032)
• Table 14: Line-wise Chemo Treated Cases in the US, in Thousands (2019-2032)
• Table 15: Platinum Therapy Treated Cases in the US, in Thousands (2019-2032)
• Table 16: Platin based Chemotherapy use by cancers Cases in the US, in Thousands (2019-2032)
• Table 17: Total Platinum Induced Nephrotoxicity (AKI) Cases in the US, in Thousands (2019-2032)
• Table 18: Total Incident cases of cancers using platinum based chemotherapy in EU4 and the UK, in Thousands (2019-2032)
• Table 19: Stage-wise Incident Cases of Cancer in EU4 and the UK, in Thousands (2019-2032)
• Table 20: Line-wise Chemo Treated Cases in EU4 and the UK, in Thousands (2019-2032)
• Table 21: Platinum Therapy Treated Cases in EU4 and the UK, in Thousands (2019-2032)
• Table 22: Platin based Chemotherapy use by cancers Cases in EU4 and the UK, in Thousands (2019-2032)
• Table 23: Total Platinum Induced Nephrotoxicity (AKI) Cases in EU4 and the UK, in Thousands (2019-2032)
• Table 24: Total Incident cases of cancers using platinum based chemotherapy in Japan, in Thousands (2019-2032)
• Table 25: Stage-wise Incident Cases of Cancer in Japan, in Thousands (2019-2032)
• Table 26: Line-wise Chemo Treated Cases in Japan, in Thousands (2019-2032)
• Table 27: Platinum Therapy Treated Cases in Japan, in Thousands (2019-2032)
• Table 28: Platin based Chemotherapy use by cancers Cases in Japan, in Thousands (2019-2032)
• Table 29: Total Platinum Induced Nephrotoxicity (AKI) Cases in Japan, in Thousands (2019-2032)
• Table 30: Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) Classification
• Table 31: Key Competitors - Emerging drugs
• Table 32: Tempol, Clinical Trial Description, 2022
• Table 33: RBT-3 (FeS), Clinical Trial Description, 2022
• Table 34: 5-Aminolevulinic Acid/Sodium Ferrous Citrate, Clinical Trial Description, 2022
• Table 35: Attribute Analysis of Emerging Drugs
• Table 36: Key Market Forecast Assumptions for Tempol
• Table 37: Key Market Forecast Assumptions for RBT-3
• Table 38: Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the 7MM, in USD million (2019-2032)
• Table 39: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in the 7MM, in USD million (2019-2032)
• Table 40: Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the US, in USD million (2019-2032)
• Table 41: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in the US, in USD million (2019-2032)
• Table 42: Market Size of Platinum-based Chemotherapy and Nephrotoxicity in EU4 and the UK, in USD million (2019-2032)
• Table 43: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in EU4 and the UK, in USD million (2019-2032)
• Table 44: 7MM Market Size of Platinum-based Chemotherapy and Nephrotoxicity, in USD million (2019-2032)
• Table 45: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Epidemiology and Market Methodology
• Figure 2: The Three Platinum-based Chemotherapy Drugs With Global Approval
• Figure 3: Molecular Mechanisms of Cisplatin Cytotoxicity
• Figure 4: Carboplatin: Molecular Mechanisms of Action
• Figure 5: Cellular Pharmacology of 0xaliplatin
• Figure 6: Toxicity Caused by Platinum-based Chemotherapy Drugs
• Figure 7: Risk Factors for Cisplatin Nephrotoxicity
• Figure 8: Cisplatin Nephrotoxicity
• Figure 9: Molecular Mechanisms of Cisplatin-induced Nephrotoxicity
• Figure 10: Biomarkers' Detection in AKI, AKD, and CKD
• Figure 11: Dose Reduction Methods in Patients With Decreased Renal Function
• Figure 12: Management of patients with histopathologically confirmed bladder cancer
• Figure 13: Management of patients with metastatic bladder cancer.
• Figure 14: Total Incident cases of cancers using platinum based chemotherapy in the 7MM (2019-2032)
• Figure 15: Stage-wise Incident Cases of Cancer in the 7MM (2019-2032)
• Figure 16: Line-wise Chemo Treated Cases in the 7MM (2019-2032)
• Figure 17: Platinum Therapy Treated Cases in the 7MM (2019-2032)
• Figure 18: Platin based Chemotherapy use by cancers Cases in the 7MM (2019-2032)
• Figure 19: Total Platinum Induced Nephrotoxicity (AKI) Cases in the 7MM (2019-2032)
• Figure 20: Total Incident cases of cancers using platinum based chemotherapy in the US (2019-2032)
• Figure 21: Stage-wise Incident Cases of Cancer in the US (2019-2032)
• Figure 22: Line-wise Chemo Treated Cases in the US (2019-2032)
• Figure 23: Platinum Therapy Treated Cases in the US (2019-2032)
• Figure 24: Platin based Chemotherapy use by cancers Cases in the US (2019-2032)
• Figure 25: Total Platinum Induced Nephrotoxicity (AKI) Cases in the US (2019-2032)
• Figure 26: Total Incident cases of cancers using platinum based chemotherapy in EU4 and the UK (2019-2032)
• Figure 27: Stage-wise Incident Cases of Cancer in EU4 and the UK (2019-2032)
• Figure 28: Line-wise Chemo Treated Cases in EU4 and the UK (2019-2032)
• Figure 29: Platinum Therapy Treated Cases in EU4 and the UK (2019-2032)
• Figure 30: Platin based Chemotherapy use by cancers Cases in EU4 and the UK (2019-2032)
• Figure 31: Total Platinum Induced Nephrotoxicity (AKI) Cases in EU4 and the UK (2019-2032)
• Figure 32: Total Incident cases of cancers using platinum based chemotherapy in Japan (2019-2032)
• Figure 33: Stage-wise Incident Cases of Cancer in Japan (2019-2032)
• Figure 34: Line-wise Chemo Treated Cases in Japan (2019-2032)
• Figure 35: Platinum Therapy Treated Cases in Japan (2019-2032)
• Figure 36: Platin based Chemotherapy use by cancers Cases in Japan (2019-2032)
• Figure 37: Total Platinum Induced Nephrotoxicity (AKI) Cases Japan (2019-2032)
• Figure 38: Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the 7MM, in USD million (2019-2032)
• Figure 39: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in the 7MM,in USD million (2019-2032)
• Figure 40: Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the US, in USD million (2019-2032)
• Figure 41: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in the US, in USD million (2019-2032)
• Figure 42: Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in EU4 and the UK, in USD million (2019-2032)
• Figure 43: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in EU4 and the UK, in USD million (2019-2032)
• Figure 44: Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in Japan, in USD million (2019-2032)
• Figure 45: Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in Japan, in USD million (2019-2032)

DelveInsight's " Platinum-based Chemotherapy and Nephrotoxicity - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Platinum-based Chemotherapy and Nephrotoxicity, historical and forecasted epidemiology as well as the Platinum-based Chemotherapy and Nephrotoxicity trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Platinum-based Chemotherapy and Nephrotoxicity report provides current treatment practices, emerging drugs, Platinum-based Chemotherapy and Nephrotoxicity market share of the individual therapies, current and forecasted Platinum-based Chemotherapy and Nephrotoxicity Market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Platinum-based Chemotherapy and Nephrotoxicity treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032.

Platinum-based Chemotherapy and Nephrotoxicity Understanding and Treatment Algorithm

The DelveInsight's Platinum-based Chemotherapy and Nephrotoxicity market report gives a thorough understanding of Platinum-based Chemotherapy and Nephrotoxicity by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Chemotherapy is one of the most common cancer treatments, and it involves taking medications designed to destroy cancer cells. Many different types of chemotherapy drugs are used to treat cancer, and one of the most frequently used categories is platinum-based chemotherapy drugs. Platinum-based Chemotherapy and Nephrotoxicity is a renal dysfunction that occurs as a result of exposure to platinum based chemotherapy.

Platinum-based Chemotherapy and Nephrotoxicity can present in several ways. However, the most serious and one of the more common presentations is acute kidney injury (AKI). Symptoms include hypomagnesemia, distal renal tubular acidosis, hyperuricemia, transient proteinuria, erythropoietin deficiency, and others. The major complications in Platinum-based Chemotherapy and Nephrotoxicity is ischemic damage to the kidney. Platinum induced nephrotoxicity (AKI) incidence can be varied by different platinum containing drugs like Cisplatin, Carboplatin etc.

The diagnostic criteria of Platinum-based Chemotherapy and Nephrotoxicity have evolved from a cluster of clinical symptoms and laboratory findings of suspected cases. Evaluation of nephrotoxicity through blood tests includes the measurements of blood urea nitrogen (BUN), the concentration of serum creatinine, glomerular filtration rate, and creatinine clearance.

Biomarkers testing for functional and damage biomarkers like SCr (serum creatinine) level and urine output are two functional biomarkers widely employed in clinical practice for Platinum-based Chemotherapy and Nephrotoxicity. In contrast to functional biomarkers, damage-associated biomarkers are specific to tubular injury and can potentially identify patients at higher risk of developing AKI. This is particularly relevant in clinically silent cases or subclinical AKI, where creatinine level and urine output measurements are unreliable.

Treatment

There are currently no disease-modifying treatments for Platinum-based Chemotherapy and Nephrotoxicity. Preventive care is the mainstay of managing Platinum-based Chemotherapy and Nephrotoxicity. The mainstay approach to prevent cisplatin-induced nephrotoxicity is administering intravenous (IV) hydration with isotonic saline to increase renal blood flow and decrease the half-life of cisplatin and urinary cisplatin concentration. Amifostine is the only approved drug for the preventive care of nephrotoxicity in ovarian cancer patients, and several pharmacological options are used off-label. Amifostine has been thought to be particularly relevant in patients with a high risk for renal toxicity, such as elderly patients.

Platinum-based Chemotherapy and Nephrotoxicity Epidemiology

The Platinum-based Chemotherapy and Nephrotoxicity epidemiology division provides insights about historical and current Platinum-based Chemotherapy and Nephrotoxicity patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In 2021, Total Platinum Induced Nephrotoxicity (AKI) Cases in the 7MM were 168,933 in the 7MM which are expected to grow during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted Platinum-based Chemotherapy and Nephrotoxicity epidemiology [segmented as Total Incident cases of cancers using platinum based chemotherapy, Stage-wise Incident Cases of Cancer, Line-wise Chemo Treated Cases, Platinum therapy Treated Patients, and Platinum induced nephrotoxicity (AKI) by therapy] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Platinum-based Chemotherapy and Nephrotoxicity Epidemiology

The epidemiology segment also provides the Platinum-based Chemotherapy and Nephrotoxicity epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

As per DelveInsight's estimates, among the 7MM, United States had the highest platinum induced nephrotoxicity (AKI) cases with 63,122 cases in the year 2021, estimated to increase by 2032.

In 2021, total platinum induced nephrotoxicity (AKI) cases were 70,798 cases, in EU4 and the UK, which might decrease by 2032.

According to the DelveInsight's analysis, among EU4 and the UK, Germany had the highest platinum induced nephrotoxicity (AKI) cases with 20,750 cases, in 2021.

In 2021, total platinum induced nephrotoxicity (AKI) cases in Japan were 33,453 cases that might decrease by 2032.

Platinum-based Chemotherapy and Nephrotoxicity Drug Chapters

The drug chapter segment of the Platinum-based Chemotherapy and Nephrotoxicity report encloses the detailed analysis of Platinum-based Chemotherapy and Nephrotoxicity marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Platinum-based Chemotherapy and Nephrotoxicity clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Platinum-based Chemotherapy and Nephrotoxicity treatment.

Platinum-based Chemotherapy and Nephrotoxicity Outlook

The Platinum-based Chemotherapy and Nephrotoxicity outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Platinum-based Chemotherapy and Nephrotoxicity market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of Platinum-based Chemotherapy and Nephrotoxicity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Platinum-based Chemotherapy and Nephrotoxicity market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

The Platinum-based Chemotherapy and Nephrotoxicity market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of Platinum-based Chemotherapy and Nephrotoxicity in the seven major markets is expected to increase during the study period (2019-2032).

In 2021, the total market size of Platinum-based Chemotherapy and Nephrotoxicity in the 7MM was USD 654.8 million which is expected to rise during the study period (2019-2032).

The United States Market Outlook

The total market size of Platinum-based Chemotherapy and Nephrotoxicity in the United States accounted for USD 332.4 million in 2021 which is expected to rise during the study period (2019-2032).

EU5 Countries: Market Outlook

In EU5, the total market size of Platinum-based Chemotherapy and Nephrotoxicity was USD 203.9 million in 2021, which is expected to rise during the study period (2019-2032).

Japan Market Outlook

In Japan, the total market size of Platinum-based Chemotherapy and Nephrotoxicity was USD 118.5 million in 2021, which is expected to rise during the study period (2019-2032).

Platinum-based Chemotherapy and Nephrotoxicity Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Platinum-based Chemotherapy and Nephrotoxicity market or expected to get launched in the market during the study period 2019-2032. The analysis covers Platinum-based Chemotherapy and Nephrotoxicity market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Platinum-based Chemotherapy and Nephrotoxicity Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Platinum-based Chemotherapy and Nephrotoxicity key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for Platinum-based Chemotherapy and Nephrotoxicity emerging therapies.

Reimbursement Scenario in Platinum-based Chemotherapy and Nephrotoxicity

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Platinum-based Chemotherapy and Nephrotoxicity domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Platinum-based Chemotherapy and Nephrotoxicity market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Platinum-based Chemotherapy and Nephrotoxicity by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Platinum-based Chemotherapy and Nephrotoxicity, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Platinum-based Chemotherapy and Nephrotoxicity epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Platinum-based Chemotherapy and Nephrotoxicity are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Platinum-based Chemotherapy and Nephrotoxicity market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Platinum-based Chemotherapy and Nephrotoxicity market.

Report Highlights:

• In the coming years, the Platinum-based Chemotherapy and Nephrotoxicity market is set to change due to the upcoming therapies with novel route of administrations which are under investigation and ongoing research in the cUTI; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Platinum-based Chemotherapy and Nephrotoxicity R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Complicated Urinary Tract Infection. The launch of emerging therapies will significantly impact the Platinum-based Chemotherapy and Nephrotoxicity market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Complicated Urinary Tract Infection.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Platinum-based Chemotherapy and Nephrotoxicity Report Insights

• Patient Population
• Therapeutic Approaches
• Platinum-based Chemotherapy and Nephrotoxicity Pipeline Analysis
• Platinum-based Chemotherapy and Nephrotoxicity Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Platinum-based Chemotherapy and Nephrotoxicity Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Platinum-based Chemotherapy and Nephrotoxicity Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Platinum-based Chemotherapy and Nephrotoxicity Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Platinum-based Chemotherapy and Nephrotoxicity drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Platinum-based Chemotherapy and Nephrotoxicity total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Platinum-based Chemotherapy and Nephrotoxicity market size during the forecast period (2019-2032)?
• At what CAGR, the Platinum-based Chemotherapy and Nephrotoxicity market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Platinum-based Chemotherapy and Nephrotoxicity market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Platinum-based Chemotherapy and Nephrotoxicity market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Complicated Urinary Tract Infection?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Platinum-based Chemotherapy and Nephrotoxicity patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Platinum-based Chemotherapy and Nephrotoxicity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Complicated Urinary Tract Infection?
• Out of all 7MM countries, which country would have the highest prevalent population of Platinum-based Chemotherapy and Nephrotoxicity during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Platinum-based Chemotherapy and Nephrotoxicity treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Platinum-based Chemotherapy and Nephrotoxicity in the USA, Europe, and Japan?
• What are the Platinum-based Chemotherapy and Nephrotoxicity marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Complicated Urinary Tract Infection?
• How many therapies are in-development by each company for Platinum-based Chemotherapy and Nephrotoxicity treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Platinum-based Chemotherapy and Nephrotoxicity treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Platinum-based Chemotherapy and Nephrotoxicity therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Platinum-based Chemotherapy and Nephrotoxicity and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Complicated Urinary Tract Infection?
• What are the global historical and forecasted markets of Complicated Urinary Tract Infection?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Platinum-based Chemotherapy and Nephrotoxicity market
• To understand the future market competition in the Platinum-based Chemotherapy and Nephrotoxicity market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Platinum-based Chemotherapy and Nephrotoxicity in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Platinum-based Chemotherapy and Nephrotoxicity market
• To understand the future market competition in the Platinum-based Chemotherapy and Nephrotoxicity market

Table of Contents

1. Key Insights

2. Report Introduction

3. Platinum-based Chemotherapy and Nephrotoxicity Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Platinum-based Chemotherapy and Nephrotoxicity by therapies in 2019
• 3.2. Market Share (%) Distribution of Platinum-based Chemotherapy and Nephrotoxicity by therapies in 2032

4. Executive Summary of Platinum-based Chemotherapy and Nephrotoxicity

5. Key Events

• 5.1. Future Prospectus

6. Epidemiology and Market Methodology

7. Disease Background and Overview: Platinum-based Chemotherapy and Nephrotoxicity

• 7.1. Introduction
• 7.2. Platinum-based Chemotherapy Agents
• 7.3. The Mechanism of Platinum-drug Toxicity
• 7.4. Cisplatin Nephrotoxicity
• 7.5. Renal Manifestation
• 7.6. Risk Factors for Cisplatin Nephrotoxicity
• 7.7. Pathophysiology
  • 7.7.1. Proximal tubular injury
  • 7.7.2. Oxidative Stress
  • 7.7.3. Renal hemodynamics and vascular injury
  • 7.7.4. Inflammation
• 7.8. Diagnosis
  • 7.8.1. Diagnosis based on biomarkers
• 7.9. Treatment
  • 7.9.1. Guidelines for treatment of renal injury during cancer chemotherapy 2016
  • 7.9.2. Bladder cancer: ESMO Clinical Practice Guideline for treatment and follow-up 2021

8. Patient Journey

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale 7MM
• 9.3. Epidemiology Scenario in the 7MM
  • 9.3.1. Total Incident cases of cancers using platinum based chemotherapy in the 7MM
  • 9.3.2. Stage-wise Incident Cases of Cancer in the 7MM
  • 9.3.3. Line-wise Chemo Treated Cases in the 7MM
  • 9.3.4. Platinum Therapy Treated Cases in the 7MM
  • 9.3.5. Platin based Chemotherapy use by cancers Cases in the 7MM
  • 9.3.6. Total Platinum Induced Nephrotoxicity (AKI) Cases in the 7MM
• 9.4. Epidemiology Scenario in the United States
  • 9.4.1. Total Incident cases of cancers using platinum based chemotherapy in the United States
  • 9.4.2. Stage-wise Incident Cases of Cancer in the United States
  • 9.4.3. Line-wise Chemo Treated Cases in the United States
  • 9.4.4. Platinum Therapy Treated Cases in the United States
  • 9.4.5. Platin based Chemotherapy use by cancers Cases in the United states
  • 9.4.6. Total Platinum Induced Nephrotoxicity (AKI) Cases in the United States
• 9.5. Epidemiology Scenario in EU4 and the UK
  • 9.5.1. Total Incident cases of cancers using platinum based chemotherapy in EU4 and the UK
  • 9.5.2. Stage-wise Incident Cases of Cancer in EU4 and the UK
  • 9.5.3. Line-wise Chemo Treated Cases in EU4 and the UK
  • 9.5.4. Platinum Therapy Treated Cases in EU4 and the UK
  • 9.5.5. Platin based Chemotherapy use by cancers Cases in EU4 and the UK
  • 9.5.6. Total Platinum Induced Nephrotoxicity (AKI) Cases in EU4 and the UK
• 9.6. Epidemiology Scenario in Japan
  • 9.6.1. Total Incident cases of cancers using platinum based chemotherapy in Japan
  • 9.6.2. Stage-wise Incident Cases of Cancer in Japan
  • 9.6.3. Line-wise Chemo Treated Cases in Japan
  • 9.6.4. Platinum Therapy Treated Cases in Japan
  • 9.6.5. Platin based Chemotherapy use by cancers Cases in Japan
  • 9.6.6. Total Platinum Induced Nephrotoxicity (AKI) Cases in Japan

10. Key Endpoints in Platinum-based Chemotherapy and Nephrotoxicity Clinical Trials

11. Emerging Therapies

• 11.1. Key Competitors
• 11.2. Tempol: Matrix Biomed
  • 11.2.1. Product description
  • 11.2.2. Other developmental activities
  • 11.2.3. Clinical development
• 11.3. RBT-3 (FeS): Renibus Therapeutics
  • 11.3.1. Product description
  • 11.3.2. Other developmental activities
  • 11.3.3. Clinical development
  • 11.3.4. Safety and efficacy
• 11.4. 5-Aminolevulinic acid/sodium ferrous citrate (SPP-003): SBI Pharmaceuticals
  • 11.4.1. Product description
  • 11.4.2. Clinical development
  • 11.4.3. Safety and efficacy

12. Conjoint Analysis

• 12.1. Attribute Analysis
• 12.2. Key Market Forecast Assumptions

13. Platinum-based Chemotherapy and Nephrotoxicity: 7 Major Market Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the 7MM
  • 13.3.1. Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the 7MM
  • 13.3.2. Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in the 7MM
• 13.4. Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the United States
  • 13.4.1. Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in the United States
  • 13.4.2. Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in the United States
• 13.5. Market Size of Platinum-based Chemotherapy and Nephrotoxicity in EU4 and the UK
  • 13.5.1. Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in EU4 and the UK
  • 13.5.2. Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in EU4 and the UK
• 13.6. Market Size of Platinum-based Chemotherapy and Nephrotoxicity in Japan
  • 13.6.1. Total Market Size of Platinum-based Chemotherapy and Nephrotoxicity in Japan
  • 13.6.2. Market Size of Platinum-based Chemotherapy and Nephrotoxicity by Therapies in Japan

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

• 17.1. Acronyms and Abbreviations
• 17.2. Bibliography
• 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight